Engineering ex vivo T-cell expansion for CAR-T therapy: bridging biological fidelity and bioprocess scalability through platforms, functional consumables, and integrated closed manufacturing
- DOI
- 10.3389/fimmu.2026.1981337
- Published
- 2026-10-20
- Container
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2026.1981337,
title = {Engineering ex vivo T-cell expansion for CAR-T therapy: bridging biological fidelity and bioprocess scalability through platforms, functional consumables, and integrated closed manufacturing},
author = {Qingzhi Wu and Menghui Jiang and Yuanyuan Li and Hui Huo and Haoyuan Cheng and Tian Jia and Yushu Wang and Ziwei Wang and Mengdie Ji and Jingjing Lin and Deyue Jiang and Nuo Zhang and Fuliang Chen},
year = {2026},
journal = {Frontiers in Immunology},
doi = {10.3389/fimmu.2026.1981337},
url = {https://doi.org/10.3389/fimmu.2026.1981337}
}RIS
TY - JOUR TI - Engineering ex vivo T-cell expansion for CAR-T therapy: bridging biological fidelity and bioprocess scalability through platforms, functional consumables, and integrated closed manufacturing AU - Qingzhi Wu AU - Menghui Jiang AU - Yuanyuan Li AU - Hui Huo AU - Haoyuan Cheng AU - Tian Jia AU - Yushu Wang AU - Ziwei Wang AU - Mengdie Ji AU - Jingjing Lin AU - Deyue Jiang AU - Nuo Zhang AU - Fuliang Chen PY - 2026 JO - Frontiers in Immunology DO - 10.3389/fimmu.2026.1981337 UR - https://doi.org/10.3389/fimmu.2026.1981337 ER -
APA
Wu, Q., Jiang, M., Li, Y., Huo, H., Cheng, H., Jia, T., Wang, Y., Wang, Z., Ji, M., Lin, J., Jiang, D., Zhang, N., & Chen, F. (2026). Engineering ex vivo T-cell expansion for CAR-T therapy: bridging biological fidelity and bioprocess scalability through platforms, functional consumables, and integrated closed manufacturing. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1981337
Source records
- crossref · retrieved 2026-11-06T08:13:49.040Z